Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYan GaoLPLiqin PingYHYunhong Huang

Discussion

Loading...

Member takes

Overview

Phase II trial shows 5-year PFS of 60.5% in indolent B-cell lymphoma, suggesting rituximab plus interferon may enhance treatment efficacy.

Key Points

  • To evaluate the long-term outcomes of rituximab plus pegylated interferon α-2b in untreated indolent B-cell lymphoma.
  • Conducted a phase II trial (RIPPLE) with treatment-naïve iBCL patients.
  • Ind induction therapy included rituximab biosimilar and Peg-IFN-α2b for 6 cycles, followed by maintenance.
  • Assessment of overall response rate (ORR), complete response (CR), and safety in the cohort.
  • 57 patients were enrolled, median age of 54 years.
  • Overall response rate was 71.9%, with a complete response rate of 56.1%.
  • 5-year progression-free survival (PFS) was 60.5%, and overall survival (OS) was 91.2%.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dffdhttps://doi.org/10.1182/blood-2025-5375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up2024 · 11 citations
  2. 2Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP2025
  3. 3Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience2024 · 2 citations
  4. 4SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY2023 · 4 citations
  5. 5SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma2026